A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Purpose

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Conditions

  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder

Eligibility

Eligible Ages
Between 18 Years and 74 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults ≥18 and ≤74 years of age who experienced their first major depressive episode (MDE) prior to 50 years of age. - Body Mass Index (BMI) ≥18 kg/m2 and ≤40 kg/m2. - Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder and is currently in a MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI). - Current MDE must has a duration of ≥4 weeks and ≤12 months.

Exclusion Criteria

  • Participant has any type of major depressive disorder (MDD) diagnosis, including MDD with psychotic features, MDD with catatonia, MDD with seasonal pattern, or postpartum depression. - Participant has any nonbipolar psychiatric diagnosis. - Participant has a substance use disorder (excluding tobacco) within the 6 months prior to screening visit. - Participant has a symptomatic eating disorder within the 12 months prior to screening visit. - Participant has a Young Mania Rating Scale (YMRS) score >12 points at screening visit or randomization. - Participant has been hospitalized for mania within the 30 days prior to screening visit. - Participant is considered treatment-resistant in the current bipolar depressive episode, defined as having treatment resistance (no remission) to ≥2 different medications approved by the regional regulatory authority at an adequate dose (per regulatory approved label) and for an adequate duration (at least 6 weeks). - Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 2 years, or ≥2 lifetime suicide attempts. - Participant has self-injurious behavior without intent to die in the 12 months prior to screening. - Participant has used antidepressants, mood stabilizers, anticonvulsants, antipsychotics, or other prohibited medications within the 2 weeks or within a period less than 5 times the drug's half-life, whichever is longer prior to randomization. - Participants with medical conditions that may interfere with the purpose or conduct of the study. - Participant is pregnant, breastfeeding, or planning to become pregnant.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Azetukalner 		Azetukalner 20 mg
  • Drug: Azetukalner
    Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
    Other names:
    • XEN1101
Placebo Comparator
Placebo 		Placebo
  • Drug: Placebo
    Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks

Recruiting Locations

More Details

Status
Recruiting
Sponsor
Xenon Pharmaceuticals Inc.

Study Contact

Xenon Medical Affairs
1-604-484-3300
XenonCares@xenon-pharma.com

If you are in crisis please dial 988 for the Suicide & Crisis Lifeline. Please note: ADAA is not a direct service organization. ADAA does not provide psychiatric, psychological, or medical advice, diagnosis, or treatment.
Donate Today Find a Therapist